480
Participants
Start Date
September 30, 2021
Primary Completion Date
April 12, 2024
Study Completion Date
April 12, 2024
Lumateperone
Lumateperone 42 mg capsules administered orally, once daily.
Placebo
Matching capsules administered orally, once daily.
Clinical Site, Sofia
Clinical Site, Sofia
Clinical Site, Plovdiv
Clinical Site, Córdoba
Clinical Site, Córdoba
Clinical Site, Targovishte
Clinical Site, Brooklyn
Clinical Site, Stockholm
Clinical Site, Allentown
Clinical Site, Schwerin
Clinical Site, Media
Clinical Site, Plymouth Meeting
Clinical Site, Hamburg
Clinical Site, Gaithersburg
Clinical Site, Lund
Clinical Site, Westerstede
Clinical Site, Charlotte
Clinical Site, Atlanta
Clinical Site, Palm Bay
Clinical Site, West Palm Beach
Clinical Site, Flowood
Clinical Site, Bad Homburg
Clinical Site, Overland Park
Clinical Site, Little Rock
Clinical Site, Rogers
Clinical site, Freiburg im Breisgau
Clinical Site, Oulu
Clinical Site, San Diego
Clinical Site, Riverside
Clinical Site, Newport Beach
Clinical Site, Bellevue
Clinical Site, Buenos Aires
Clinical Site, Córdoba
Clinical Site, Córdoba
Clinical Site, Mendoza
Clinical Site, Rosario
Clinical Site, Buenos Aires
Clinical Site, Helsinki
Clinical Site, Mittweida
Clinical Site, Bełchatów
Clinical Site, Bialystok
Clinical Site, Bialystok
Clinical Site, Bialystok
Clinical Site, Bydgoszcz
Clinical Site, Gdansk
Clinical Site, Gorlice
Clinical Site, Leszno
Clinical Site, Pruszcz Gdański
Clinical Site, Torun
Clinical Site, Wroclaw
Lead Sponsor
Intra-Cellular Therapies, Inc.
INDUSTRY